window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Eli Lilly

  • Clinical Trials,Drug Development,Patient Centricity,Regulatory Affairs

    NICE backs mirikizumab for treatment-resistant Crohn’s disease

    The National Institute for Health and Care Excellence (NICE) has [...]

    May 30, 2025
  • Artificial Intelligence,Biologics & Biosimilars,Drug Development

    Alchemab strikes $415m licensing deal with Lilly for ALS candidate ATLX-1282

    UK-based Alchemab Therapeutics has signed a landmark licensing agreement with [...]

    May 20, 2025
  • Biologics & Biosimilars,Cell & Gene Therapy,Partnerships & Funding

    Creyon Bio and Lilly collaborate on AI-designed RNA-targeted oligo therapies

    Partnership aims to accelerate development using computational drug design Creyon [...]

    May 1, 2025
  • Clinical Trials

    Eli Lilly’s Lepodisiran cuts heart disease risk factor by 94% in Phase 2 trial

    April 24, 2025
Previous12

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy
    Categories: Clinical Development, Clinical Trials, Digital Health, Funding, Mental health, Neurosciences, Pharmaceuticals and therapeutics
  • Kainova Therapeutics doses first patient in Europe in phase 1/2 anti-CCR8 antibody trial
    Categories: Clinical Trials, Oncology
  • START appoints Salwan Al Mutar to lead clinical research in Dallas-Fort Worth
    Categories: Clinical Development, Clinical Trials, Healthcare leadership, Oncology
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top